Latest news with #Juvenescence
Yahoo
4 days ago
- Business
- Yahoo
Juvenescence enhances AI drug discovery with Ro5 acquisition
Juvenescence has acquired drug discovery company Ro5, a move that enhances its AI/machine learning capabilities and improves research and development capabilities. The acquisition forms a key part of Juvenescence's partnership with the Abu Dhabi global healthcare company M42, which was announced in April 2025. Ro5's platform utilises a biomedical knowledge graph containing more than 85 million nodes and 400m relationships to find new connections in biological processes and enable evaluation of drug targets based on therapeutic, biological and market potential. Ro5's AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Juvenescence CBE and CEO Dr Richard Marshall stated: 'We are delighted to welcome the Ro5 team and the company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. 'This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' The acquisition follows the recent announcement by Juvenescence of a $76m first close of its Series B-1 financing round, led by investor M42. Follow-on investments came from existing investors, with the second close anticipated in the third quarter of 2025. The funds will support clinical milestones along with AI-driven development across Juvenescence's portfolio, targeting diseases related to ageing. Incorporating Ro5's AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments. This integration will reinforce Juvenescence's pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Ro5 CEO Charles Dazler Knuff added: 'Together with our partners at M42, we are laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' "Juvenescence enhances AI drug discovery with Ro5 acquisition" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
Yahoo
5 days ago
- Business
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
Yahoo
21-05-2025
- Business
- Yahoo
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi's M42 alongside strategic partnership
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi's M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking strategic partnership with M42 to collaborate in drug discovery Juvenescence aims to complete the financing in Q3 2025 to advance clinical pipeline targeting age-related diseases Ramsey, Isle of Man, 21 May 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce that it has secured a total of $76m in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated to complete in the third quarter of 2025. The financing will enable Juvenescence to continue advancing its portfolio of therapeutics into clinical development and deliver critical clinical readouts for its core medicine pipeline. The investment by M42 is part of a wider strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases. Juvenescence and M42 will establish a leading drug development hub in Abu Dhabi, led by an unrivalled team, to build a therapeutics pipeline to extend healthy lifespan. Leveraging M42's deep expertise in digital healthcare data, genomics, bioanalysis, and its clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, the collaboration will drive breakthroughs in therapeutic development, enhance disease understanding, and enable fast-tracking of clinical development. As well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organisations both in UAE, and globally and to support the wider life sciences strategy in Abu Dhabi. A Joint Steering Committee comprised of senior executives from both companies will oversee the execution of this partnership. Dr Richard Marshall CBE, CEO of Juvenescence, said: 'We are grateful for the continued support of our investors, including new investor and strategic partner M42, who have joined us on this remarkable journey. Our partnership with M42 signifies a shared commitment to developing sustainable, long-term collaborations. Together, we are excited about the opportunity to help build a leading life-sciences hub in Abu Dhabi and establish a pipeline of innovative therapeutics that will improve the lives of millions of patients. 'Our world class team of senior drug developers, together with our academic and biotech partners, are excited and proud that Juvenescence is now a clinical stage biotechnology company and our AI expansion will speed up the clinical development of these assets." Dr Fahed Al MarzooqiCEO of M42's Integrated Health Solutions platform and acting CEO of its AI Life Sciences platform, added: 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision and progress, delivering transformative therapies from Abu Dhabi to the world.' -Ends- About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Program, M42 runs Abu Dhabi BioBank and ADHDS, a global tech-enabled healthcare company operating Malaffi. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Khaleej Times
16-04-2025
- Health
- Khaleej Times
Abu Dhabi's M42 partners with UK firm to develop AI-driven therapeutics for age-related diseases
Abu Dhabi's M42 has announced a partnership and investment in UK-based longevity biotech leader Juvenescence. The new alliance is aimed at discovering and developing AI-enabled therapeutics to advance the treatment of life-threatening and age-related diseases and improve healthy lifespan. M42 and Juvenescence will harness the power of artificial intelligence, genomics, and biobanking to accelerate clinical trials and bring transformative medicines to market faster. The collaboration was revealed during Abu Dhabi Global Health Week (ADGHW), where M42 is a Foundational Partner. Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, 'With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges.' Age-related conditions such as cardiovascular disease, neurodegeneration, and metabolic disorders are becoming increasingly prevalent due to growing global life expectancy. With the UAE actively pursuing advanced solutions to address the healthcare needs of its aging population, this partnership comes at a critical time. Al Nowais added, 'With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science and on the future of health.' From Abu Dhabi to the world Further, the partnership will aim to identify novel drug targets and therapeutics, as well as explore collaboration in R&D with leading academic and research organisations globally and support the development of the country's biotechnology strategy. Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added, 'By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress — delivering transformative therapies from Abu Dhabi to the world.' Dr Richard Marshall, Chief Executive Officer at Juvenescence, said, ' Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the health span of patients globally.'
